| Biological Information | |
|---|---|
| Background Information: | ABT-737 is a small molecule BH3 mimetic inhibitor of the anti-apoptotic members of the BCL-2 family, selective for BCL-2, BCL-XL, and BCL-W (EC50=78.7, 30.3, and 197.8nM, respectively). Developed by AbbVie, it failed in clinical trials due to toxicity issues, but was proven efficacious with various radiation therapies in triggering apoptosis in cancer cells and xenografts. Provided as 5 mg of dry powder. |
| Target Name: | ABT-737 |
| Usage | |
| Product Type: | Control Ligands & Inhibitors |
| Application: | Drug Discovery & Development |
| Storage Conditions: | Store at ≤-20°C. Please avoid multiple freeze/thaw cycles. |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
| Additional Information | |
| Brand: | DiscoverX |
ABT-737
ABT-737 is an antagonist for BCL2 and BCL2L1. This product is provided as 5 mg of dry powder.
Datasheets
92-1151 Datasheet
View Document